

Katherine E. Reed, Ph.D.
Staff Vice President

3M Environmental Technology
and Safety Services

900 Bush Avenue
Building 42-2E-26
PO Box 33331
St Paul, MN 55133-3331
651 778 4331

2pp

8EHQ-1102-00373

8EHQ-80-373

MR63436

AR 226-1138

3M

CERTIFIED MAIL

Contain NO CBI

October 30, 2002

Document Processing Center (7407M)
EPA East - Room 6428 Attn: Section 8(e)
Office of Pollution Prevention and Toxics
US EPA
1200 Pennsylvania Ave., NW
Washington, DC 20460-0001

2002 NOV -5 AM 11:27

RECEIVED
OCT 08 10

TSCA 8(E) SUBSTANTIAL RISK NOTICE ON: Perfluorohexane sulfonate potassium salt
Reference 8EHQ-1180-373, 374

Dear Sir:

3M recently sponsored an "Oral (Gavage) Combined Repeated Dose Toxicity with the Reproductive/Developmental Toxicity Screening Test" Study of perfluorohexane sulfonate potassium salt (PFHS), T-7706. The study was conducted at Argus Research Charles River Laboratories, Horsham, Pennsylvania. The preliminary draft results include certain findings that appear appropriate for TSCA section 8(e) submission.

2002 NOV 21 AM 11:53

RECEIVED
OCT 10 10

Parental male rats were dosed for at least 42 days. Parental females were dosed for approximately 60 days. No PFHS related effects were observed in the parental females. The adverse effects noted in parental male rats exposed to PFHS included: (a) an increased absolute liver weight; an increased liver-to-body-weight ratio; and a liver-to-brain-weight ratio for both the 3 and 10 mg/kg/day doses; (b) decreased average values for cholesterol in the 0.3, 1, 3 and 10 mg/kg/day doses; (c) decreased triglycerides in the 10 mg/kg/day dose; (d) minimal to moderate enlargement of centrilobular hepatocytes in the 3 and 10 mg/kg/day doses; and (e) increased incidence of thyroid follicular cells hypertrophy and hyperplasia in the thyroid glands of males in the 3 and 10 mg/kg/day doses. There were no signs of neurological, developmental or reproductive effects.

A copy of this study report will be sent to EPA when received.

A previously reported Exploratory 28-day Oral Toxicity Study conducted with PFHS, among other compounds, demonstrated some of these same adverse effects. See Letter from 3M to 8(e) Docket, August 21, 2000 (requesting this and other studies to be moved from AR-226 to the 8EHQ-1180-373, 374 docket).

EPA-OTS



000811850N

Office of Pollution Prevention and Toxics

Page No. 2

October 30, 2002

Please contact Dr. John Butenhoff, 3M Corporate Toxicology and Regulatory Services,
651-733-1962, for further information.

Sincerely,

A handwritten signature in cursive script that reads "Katherine E. Reed". The signature is written in dark ink and is positioned above the printed name and title.

Katherine E. Reed

Staff Vice President, Environmental Technology and Safety Services